Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Winner

Vertex Pharmaceuticals ( VRTX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.3%. By the end of trading, Vertex Pharmaceuticals rose $3.06 (3.8%) to $84.70 on light volume. Throughout the day, 1,450,792 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2,537,400 shares. The stock ranged in a price between $81.86-$84.78 after having opened the day at $82.05 as compared to the previous trading day's close of $81.64. Other companies within the Drugs industry that increased today were: Rexahn Pharmaceuticals ( RNN), up 16.8%, Alnylam Pharmaceuticals ( ALNY), up 15.8%, Rockwell Medical ( RMTI), up 15.7% and Bacterin International Holdings ( BONE), up 14.9%.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.7 billion and is part of the health care sector. Shares are up 90.9% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

On the negative front, Mast Therapeutics ( MSTX), down 34.5%, Merrimack Pharmaceuticals ( MACK), down 28.0%, Inovio Pharmaceuticals ( INO), down 11.6% and CytRx Corporation ( CYTR), down 8.1% , were all laggards within the drugs industry with Celldex Therapeutics ( CLDX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers